Introduction

A patent infringement dispute over proprietary cannabis extraction methods ended in voluntary dismissal with prejudice in the U.S. District Court for the Western District of Washington on March 11, 2024. In Capna IP Capital, LLC v. ETZ Hayim Holdings, SPC (Case No. 2:23-cv-00281), the plaintiff asserted two U.S. patents covering methods to reduce chlorophyll co-extraction during essential oil and aromatic isolate separation — a technically specialized area with growing commercial significance in cannabis and botanical processing industries.

The case resolved 377 days after filing through a stipulated dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(ii), with each party bearing its own costs and attorney fees. No damages were awarded and no injunctive relief was granted. For patent attorneys, IP professionals, and R&D teams operating in the extraction technology space, this outcome offers meaningful procedural and strategic lessons — particularly regarding patent assertion strategies, defense positioning, and the economics of pre-trial resolution in niche biotechnology patent disputes.

Case Overview

The Parties

The Patents at Issue

Two U.S. patents formed the foundation of the infringement claims. Both relate to methods to reduce chlorophyll co-extraction through extraction of select moieties, essential oils, and aromatic isolates. Chlorophyll co-extraction is a persistent challenge in cannabis and botanical processing — unwanted chlorophyll compounds degrade product quality, flavor profiles, and downstream refinement efficiency.

• • U.S. Patent No. 10,507,407 B2 (Application No. 16/023,531)
• • U.S. Patent No. 10,814,248 B2 (Application No. 16/681,765)

The Accused Product

The accused products and processes involved the aforementioned extraction methods. Specific commercial products or manufacturing processes of ETZ Hayim Holdings were not publicly detailed in the case record beyond the patent claims asserted.

Legal Representation

Plaintiff’s Counsel: David Allen Lowe, Joseph J. Zito, Lawrence D. Graham, R. Scott Rhoades, and Sanford E. Warren — representing firms Lowe Graham Jones, PLLC, Warren Rhoades, LLP, and Whitestone Law.

Defendant’s Counsel: Philip P. Mann, Shan Liao, and Yan Song — from Mann Law Group PLLC and Aeon Law, PLLC.

Litigation Timeline & Procedural History

The case was filed in the U.S. District Court for the Western District of Washington. Chief Judge Thomas S. Zilly presided over the matter. The case resolved at the first-instance (district court) level, never advancing to claim construction hearings, summary judgment motions, or trial on the public record. The 377-day duration from filing to dismissal suggests the parties engaged in pre-trial discovery and negotiation before reaching a resolution. The stipulated dismissal with prejudice under Rule 41(a)(1)(A)(ii) indicates a mutual, negotiated exit rather than a unilateral withdrawal, meaning Capna IP Capital cannot refile these claims against ETZ Hayim Holdings on these patents.

The Verdict & Legal Analysis

Outcome

The case terminated via stipulated voluntary dismissal with prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(ii). Key terms of the dismissal:

• • All claims dismissed with prejudice — foreclosing any future litigation between these parties on the same patents
• • Each party bears its own costs and attorney fees — no fee-shifting under 35 U.S.C. § 285 was imposed
• • No damages awarded; no injunctive relief granted

Verdict Cause Analysis

The underlying cause of action was patent infringement of the two extraction method patents. Because the case resolved before substantive judicial rulings on claim construction or infringement, no formal findings on patent validity or infringement were made by the court.

The absence of a fee-shifting provision is notable. Under Octane Fitness, LLC v. ICON Health & Fitness, Inc. (2014), courts may award attorney fees in “exceptional” cases. The parties’ agreement that each side bears its own fees suggests neither party sought — or could successfully argue — that the opposing side’s litigation conduct was objectively unreasonable or that the case was substantively weak enough to warrant such sanctions.

The dismissal with prejudice is the critical legal element here. This resolution permanently bars Capna IP Capital from reasserting U.S. Patent Nos. 10,507,407 and 10,814,248 against ETZ Hayim Holdings. This is a significant concession by the plaintiff and may indicate: (a) a confidential licensing or settlement agreement reached outside court filings, (b) concerns about patent validity or claim scope surfaced during discovery, or (c) a commercial resolution rendering continued litigation unnecessary.

Legal Significance

This case does not produce binding precedent given its pre-trial resolution. However, it is instructive as a pattern case in cannabis-adjacent IP litigation:

• • NPE/IP holding entity assertions in the cannabis extraction space are increasing as the industry matures and patent portfolios expand
• • Stipulated dismissals in this technology area often reflect confidential licensing arrangements — a commercially pragmatic resolution common in specialized industrial process patents
• • The dual-patent assertion strategy (asserting two related patents simultaneously) is a recognized plaintiff tactic to increase litigation pressure and licensing leverage

Industry & Competitive Implications

The cannabis and botanical extraction industry has seen accelerating IP activity as proprietary processing methods become key competitive differentiators. Chlorophyll reduction and selective essential oil isolation are not merely technical niche concerns — they directly impact product purity, regulatory compliance, and consumer quality in markets including legal cannabis concentrates, hemp-derived CBD products, and botanical pharmaceutical ingredients.

Cases like Capna IP Capital v. ETZ Hayim Holdings signal that extraction method patents are actively enforced and that IP holding entities are building portfolios specifically targeting this processing layer of the cannabis supply chain. For companies operating extraction facilities — whether licensed cannabis producers, contract manufacturers, or essential oil processors — this case underscores the importance of proactive IP clearance.

The confidential resolution model reflected here is consistent with broader trends in niche biotechnology patent disputes: pre-trial settlements preserving commercial flexibility are preferred over expensive, technically complex trials where expert testimony costs can rival small company revenues.